2008-05-19 23:36:46 -

- China Yongxin Pharmaceuticals Inc. (OTCBB:CYXN), a leading manufacturer, distributor and retailer of pharmaceuticals in Northeastern China, today announced that it has retained Investor Relations International ("IRI") to lead an expanded shareholder communication program.

As investor relations counsel for China Yongxin Pharmaceuticals, Los Angeles-based IRI will raise the investment community's awareness of the Company's performance through its proprietary IR

model consisting of more comprehensive and timely corporate updates, direct communication with money managers, financial media placements and Internet marketing campaigns. The IRI program will focus on highlighting China Yongxin Pharmaceuticals' improving outlook as it begins to grow the number of its retail pharmacies in China, add new pharmaceutical products to its portfolio, increase its product distribution capabilities and expand operations geographically both in China and internationally. IRI seeks to increase the Company's capital resources by broadening its shareholder base as well as cementing the long-term loyalty of existing investors.

"We have engaged Investor Relations International to raise our profile and ensure the broad investment community fully understands our significant growth prospects," said Yongxin Liu, China Yongxin Pharmaceuticals' Chairman and CEO. "Our company is at a key point in its development as we are just beginning to expand our successful manufacturing, distribution and retail chain operations throughout China and beyond. IRI is well known for its expertise in generating investor interest, liquidity and shareholder value - all of which are critical to the success of our next growth phase."

To be added to China Yongxin Pharmaceuticals' investor lists, please contact Haris Tajyar at htajyar@irintl.com or at 818-382-9702.

About Investor Relations International

Investor Relations International (IRI), based in Los Angeles, is a leading investor relations firm serving a global client base. The principals of IRI have developed award-winning investor relations programs for a number of NYSE, Amex, Nasdaq-listed and China-based companies such as China Architectural Engineering, Cherokee, LJ International, Starwood Hotels & Resorts Worldwide, Shop NBC and others, and have assisted dozens of public companies ranging from emerging small-cap companies to multinational corporations with market capitalizations in excess of $15 billion. IRI designs and implements customized investor relations programs to meet each client's unique needs. It enjoys one of the highest client retention rates in the industry and has been ranked as one of the fastest growing private companies in America by Entrepreneur Magazine and PriceWaterhouse. For further information on IRI, please visit www.irintl.com.

About China Yongxin Pharmaceuticals, Inc.

China Yongxin Pharmaceuticals Inc. (OTCBB:CYXN) was founded in 1993 as the Changchun Yongxin Dirui Medical Co. (Yongxin), a wholesale drug distributor. Its products include Chinese traditional medicines, Chinese traditional medical teas, chemical pharmaceutical preparations, natural health products, healthy food, cosmetics, and medical equipment. It began retail operations in 2004 and, in 2005, gained franchise rights from the Medicine Shoppe(R) chain for China's Jilin Province. By the end of 2007 it had 90 retail outlets as well as wholesale distribution and manufacturing operations. Its primary market has been in Northeastern China.

Forward-Looking Statements: This news release contains certain "forward-looking statements." Forward-looking statements are based on current expectations and assumptions and are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, and many of which are beyond the Company's control. Actual results could differ materially from these forward-looking statements as a result of a number of risk factors detailed in the Company's periodic reports filed with the SEC. Given these risks and uncertainties, investors are cautioned not to place undue reliance on such forward-looking statements and no assurances can be given that such statements will be achieved. China Yongxin Pharmaceuticals, Inc. does not assume any duty to publicly update or revise the material contained herein.

Investor Relations International
Haris Tajyar, Managing Partner
818-382-9702
htajyar@irintl.com